$LFCR News

Lifecore Biomedical to Participate at CPHI Global Conference

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary

Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ...

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical Q2 Earnings Call Highlights

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market

Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer